Purines Epilepsy Lab

Purines Epilepsy Lab

Search
Skip to content
  • About the group
  • Principal Investigator
  • Team Members
    • Dr Aida Menendez Mendez
    • Mr Aidan Kenny
    • Mr Gioacchino de Leo
    • Ms Giorgia Conte
    • Dr Isabela Aparicio
    • Dr Jaideep Cherakka Kesavan
    • Mr James Morgan
    • Mr Jonathan Smith
    • Dr Laura de Diego Garcia
    • Dr Mariana Alves
  • Collaborators
    • Academic partners
    • Clinicians
    • Industry Partners
  • Research Projects
    • National funding
      • SFI CDA
    • International Funding
      • EpiPur
      • PurinesDX
      • EpiBarrier
      • TaPPiNG-EPI
      • NeoPur
  • Publications

Industry Partners

Prof Andras Dinnyes, BioTalentum Ltd

Dr Benjamin Seibt, Dr. Seibt Genomics GmbH

Dr John Ryan, Longboat Clinical Ltd

Dr Marc Ceusters, Janssen Pharmaceutica Nv

Dr Michael Hamacher, Affectis Pharmaceuticals AG

Prof Nicholas Dale, Sarissa Biomedical Ltd

P2X7 expression in the hippocampus following seizures using GFP-P2X7 reporter mice

http://purines-epilepsylab.eu/wp-content/uploads/2019/03/BLENDER-500um-p2x7-Slice_KA-2-weeks.mp4

Hot from the press!

Antagonizing Increased miR-135a Levels at the Chronic Stage of Experimental TLE Reduces Spontaneous Recurrent Seizures

Mesial temporal lobe epilepsy (mTLE) is a chronic neurological disease characterized by recurrent seizures. The antiepileptic drugs currently available to treat mTLE are ineffective in one-third of patients and lack disease-modifying effects. miRNAs, a class of small noncoding RNAs which control gene expression at the post-transcriptional level, play a key role in the pathogenesis of mTLE and other epilepsies.

Context-Specific Switch from Anti- to Pro-epileptogenic Function of the P2Y1 Receptor in Experimental Epilepsy

Extracellular ATP activates inflammatory responses to tissue injury. It is also implicated in establishing lasting network hyperexcitability in the brain by acting upon independent receptor systems. Whereas the fast-acting P2X channels have well-established roles driving neuroinflammation and increasing hyperexcitability, the slower-acting metabotropic P2Y receptors have received much less attention.

ATP release during seizures - A critical evaluation of the evidence

* Seizure-induced ATP release widely considered to contribute to epileptogenesis. * Evidence for P2 receptor role in epileptogenesis well established. * Evidence for seizure-induced ATP release mixed and dependent on model and method of detection.

Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17

Tauopathies are a group of neurodegenerative diseases characterized by the pathological aggregation of the microtubule-associated protein tau. These include more than 20 diseases, with Alzheimer's disease being the most frequent. While pathological and neurotoxic effects of tau are well documented, the mechanisms by which tau can promote neurodegeneration are less clear.

Regulation of P2X7 receptor expression and function in the brain

Because of its prominent role in driving inflammatory processes, the ATP-gated purinergic P2X7 receptor has attracted much attention over the past dec...

MicroRNA-22 Controls Aberrant Neurogenesis and Changes in Neuronal Morphology After Status Epilepticus

Prolonged seizures (status epilepticus) may drive hippocampal dysfunction and epileptogenesis, at least partly, through an elevation in neurogenesis, dysregulation of migration and aberrant dendritic arborization of newly-formed neurons. MicroRNA-22 was recently found to protect against the development of epileptic foci, but the mechanisms remain incompletely understood.

Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus

Glycogen synthase kinase-3 (GSK-3) is ubiquitously expressed throughout the brain and involved in vital molecular pathways such as cell survival and synaptic reorganization and has emerged as a potential drug target for brain diseases. A causal role for GSK-3, in particular the brain-enriched GSK-3β isoform, has been demonstrated in neurodegenerative diseases such as Alzheimer's and Huntington's, and in psychiatric diseases.

News & Events

Biomedical Biosensor SMARTChip and Probe Workshop

March 19, 2019 admin Leave a comment

The Purines Epilepsy lab Principal Investigator Tobias Engel will be a guest lecture on the Biomedical Biosensor SMARTChip and Probe Workshop hosted by Sarissa on March 22nd.

More information can be found here.

PhD candidate James Morgan wins best poster prize
News & Events

PhD candidate James Morgan wins best poster prize

March 19, 2019 admin Leave a comment

James Morgan, PhD candidate in the PurinesDX programme coordinated by our group won the best poster prize in the the Postgraduate Scholars first year only category during RCSI Research Day on March 7th, with poster entitled: “Identification of the cell-specific contribution of the P2X7 receptor to seizure-induced pathology and epilepsy development”

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Proudly powered by WordPress